30 April 2025
EMA/148455/2025
Human Medicines Division

Overview of (invented) names reviewed in April 2025 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 22 May 2025

	NRG meeting 11-12 February		NRG meeting 8-9 April		NRG meeting 3-4 June		NRG meeting 23-24 September		NRG meeting 18-19 November		2025 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	53	41	61	37							**114**	**78**
Justification for retention of (invented) name **	3	3	4	0							**7**	**3**

*Includes invented names, INN+MAH/TM and re-use applications.
**In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

	NRG meeting 11-12 February		NRG meeting 8-9 April		NRG meeting 3-4 June		NRG meeting 23-24 September		NRG meeting 18-19 November		2025 total	
	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed
Total number of objections raised	78	163	65	139							**143**	**302**
Similarity with other (invented) name	49	143	48	113							**49**	**143**
Conveys misleading therapeutic connotations	4	2	0	0							**4**	**2**
Conveys misleading pharmaceutical connotations	0	0	0	0							**0**	**0**
Similarity with INN	5	8	9	11							**14**	**19**
Inclusion of INN stem	1	1	0	0							**1**	**1**
Unacceptable qualifiers	1	1	0	0							**1**	**1**
Conveys a promotional message	8	4	1	8							**9**	**12**
Appears offensive or has an inappropriate connotation	0	0	4	1							**4**	**1**
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0							**0**	**0**
Similarity between name of prodrug and related active substance	0	0	0	0							**0**	**0**
Inclusion of common umbrella segment	0	0	0	0							**0**	**0**
Potential difficulties in pronunciation	6	1	3	1							**9**	**2**
Others	0	0	0	0							**0**	**0**

See *Guideline on the acceptability of names for human medicinal products processed through the centralised procedure (EMA/CHMP/287710/2014 - Rev. 7)* for detailed explanations of criteria used.